| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/J.CCA.2016.05.014 |
| P698 | PubMed publication ID | 27216941 |
| P50 | author | Henrik Zetterberg | Q6252048 |
| Maria Bjerke | Q97016106 | ||
| Ulf Andreasson | Q97016159 | ||
| Hugo Vanderstichele | Q106957205 | ||
| Erik Stoops | Q106957213 | ||
| Kaj Blennow | Q28321550 | ||
| Magdalena Korecka | Q57013132 | ||
| Piotr Lewczuk | Q58229544 | ||
| Erik Portelius | Q76736817 | ||
| P2093 | author name string | Heinz Schimmel | |
| Leslie M Shaw | |||
| Ingrid Zegers | |||
| Tobias Bittner | |||
| Rand G Jenkins | |||
| Andreas Leinenbach | |||
| Josef Pannee | |||
| Julia Kuhlmann | |||
| IFCC Working Group on Standardization of CSF proteins (WG-CSF) | |||
| P921 | main subject | Alzheimer's disease | Q11081 |
| biomarker | Q864574 | ||
| P304 | page(s) | 27-33 | |
| P577 | publication date | 2016-05-20 | |
| P1433 | published in | Clinica Chimica Acta | Q5133740 |
| P1476 | title | CSF Aβ1-42 - an excellent but complicated Alzheimer's biomarker - a route to standardisation | |
| P478 | volume | 467 |
| Q38653401 | A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood |
| Q59333275 | Advances in Multi-Functional Ligands and the Need for Metal-Related Pharmacology for the Management of Alzheimer Disease |
| Q92974015 | Agreement of amyloid PET and CSF biomarkers for Alzheimer's disease on Lumipulse |
| Q89840384 | Analytical and Clinical Performance of Amyloid-Beta Peptides Measurements in CSF of ADNIGO/2 Participants by an LC-MS/MS Reference Method |
| Q39251035 | Applying fluid biomarkers to Alzheimer's disease |
| Q91595666 | Biomarkers for Alzheimer's disease-preparing for a new era of disease-modifying therapies |
| Q64080494 | Bridging the Gap between Alzheimer's Disease and Alzheimer's-like Diseases in Animals |
| Q64064005 | Centiloid cut-off values for optimal agreement between PET and CSF core AD biomarkers |
| Q28595520 | Cerebrospinal Fluid Biomarkers for Alzheimer's Disease: A View of the Regulatory Science Qualification Landscape from the Coalition Against Major Diseases CSF Biomarker Team |
| Q55383590 | Cerebrospinal Fluid Biomarkers for Early and Differential Alzheimer's Disease Diagnosis. |
| Q47587631 | Cerebrospinal fluid and blood biomarkers for neurodegenerative dementias: An update of the Consensus of the Task Force on Biological Markers in Psychiatry of the World Federation of Societies of Biological Psychiatry |
| Q46254853 | Concordance Between Cerebrospinal Fluid Biomarkers with Alzheimer's Disease Pathology Between Three Independent Assay Platforms |
| Q91944531 | Critical Steps to be Taken into Consideration Before Quantification of β-Amyloid and Tau Isoforms in Blood can be Implemented in a Clinical Environment |
| Q60310921 | Current state of Alzheimer's fluid biomarkers |
| Q33599653 | Effect of long-term storage in biobanks on cerebrospinal fluid biomarker Aβ1-42, T-tau, and P-tau values |
| Q30313120 | Glutaminyl cyclase activity correlates with levels of Aβ peptides and mediators of angiogenesis in cerebrospinal fluid of Alzheimer's disease patients |
| Q104111087 | Increasing the reproducibility of fluid biomarker studies in neurodegenerative studies |
| Q40193607 | Intracranial IL-17A overexpression decreases cerebral amyloid angiopathy by upregulation of ABCA1 in an animal model of Alzheimer's disease. |
| Q64814709 | Mass spectrometry: A platform for biomarker discovery and validation for Alzheimer's and Parkinson's diseases |
| Q54946040 | Molecular biomarkers of Alzheimer's disease: progress and prospects. |
| Q47407570 | Multiplexing Biomarker Methods, Proteomics and Considerations for Alzheimer's Disease |
| Q52589491 | NIA-AA Research Framework: Toward a biological definition of Alzheimer's disease. |
| Q89945308 | Perspectives in fluid biomarkers in neurodegeneration from the 2019 biomarkers in neurodegenerative diseases course-a joint PhD student course at University College London and University of Gothenburg |
| Q89984102 | Plasma P-tau181 in Alzheimer's disease: relationship to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to Alzheimer's dementia |
| Q59802837 | Preanalytical approaches to improve recovery of amyloid-β peptides from CSF as measured by immunological or mass spectrometry-based assays |
| Q42643417 | Preclinical effects of APOE ε4 on cerebrospinal fluid Aβ42 concentrations |
| Q93163161 | Protective effects of Akkermansia muciniphila on cognitive deficits and amyloid pathology in a mouse model of Alzheimer's disease |
| Q38876654 | Recent publications from the Alzheimer's Disease Neuroimaging Initiative: Reviewing progress toward improved AD clinical trials. |
| Q33771776 | Recommendations for cerebrospinal fluid collection for the analysis by ELISA of neurogranin trunc P75, α-synuclein, and total tau in combination with Aβ(1-42)/Aβ(1-40) |
| Q50034469 | Reproducibility of Alzheimer's Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions. |
| Q52644601 | The Past and the Future of Alzheimer's Disease Fluid Biomarkers. |
| Q92030464 | Towards a unified protocol for handling of CSF before β-amyloid measurements |
| Q64067084 | Validation of the Erlangen Score Algorithm for Differential Dementia Diagnosis in Autopsy-Confirmed Subjects |
| Q90932842 | Vascular retinal biomarkers improves the detection of the likely cerebral amyloid status from hyperspectral retinal images |
Search more.